IL10 and acute kidney injury: The stability of IL‐10 and the targeting to kidney have been enhanced, showing significant amelioration of renal tubular injury and potentially preventing the transition to chronic kidney disease.[119] MSCs‐EVs have been recognized as another promising cell‐free therapy for AKI, a supramolecular hydrogel containing Arg‐Gly‐Asp (RGD) peptide has been developed to augment the MSCs‐EVs efficacy for treating AKI.